AstraZeneca Receives Reduce Rating from Kepler Capital Markets (AZN)
AstraZeneca (LON:AZN)‘s stock had its “reduce” rating reaffirmed by research analysts at Kepler Capital Markets in a report released on Monday, Analyst Ratings News reports. They currently have a GBX 2,700 ($43.68) price objective on the stock. Kepler Capital Markets’ target price would suggest a potential downside of 17.98% from the company’s current price.
Shares of AstraZeneca (LON:AZN) traded down 1.14% on Monday, hitting GBX 3291.9998. 2,245,327 shares of the company’s stock traded hands. AstraZeneca has a 1-year low of GBX 442.867 and a 1-year high of GBX 3544.50. The stock has a 50-day moving average of GBX 3210.14 and a 200-day moving average of GBX 3257.37. The company’s market cap is £41.216 billion.
AZN has been the subject of a number of other recent research reports. Analysts at Bank of America Corp. upgraded shares of AstraZeneca from an “underperform” rating to a “neutral” rating in a research note to investors on Monday, October 28th. They now have a GBX 3,400 ($55.01) price target on the stock, up previously from GBX 3,200 ($51.77). Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Friday, October 25th. They now have a GBX 3,220 ($52.10) price target on the stock. Finally, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Thursday, October 24th. They now have a GBX 2,863.67 ($46.33) price target on the stock. Twelve research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have assigned a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and an average target price of GBX 3,097.49 ($50.11).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.